Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial-Reference-Cited by-同舟云学术

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial

Published:2020-06 Issue:6 Volume:82 Page:1524-1526
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Casseres Rachel G.,Prussick Lisa,Zancanaro Pedro,Rothstein Brooke,Joshipura Deep,Saraiya Ami,Turkowski Yana,Au Shiu Chung,Alomran Abdulaziz,Abdat Rana,Abudu Minawaer,Kachuk Courtney,Dumont Nicole,Gottlieb Alice B.,Rosmarin David

Funder

Novartis

AbbVie

Bristol-Myers Squibb

Celgene

Dermira

Incyte

Janssen

Lilly

Merck

Pfizer

Regeneron Pharmaceuticals

XBiotech

UCB

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities;Melnik;Br J Dermatol,2018

2. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents;Matusiak;J Am Acad Dermatol,2017

3. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy;Moran;J Invest Dermatol,2017

4. Two phase 3 trials of adalimumab for hidradenitis suppurativa;Kimball;N Engl J Med,2016

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study;Dermatology and Therapy;2024-06-19

2. Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review;International Journal of Women’s Dermatology;2024-06

3. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review;Archives of Dermatological Research;2024-05-25

4. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa;Expert Opinion on Biological Therapy;2024-04-02

5. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials;British Journal of Dermatology;2024-03-12